Antipodes Healthcare Portfolio Manager, Nick Cameron highlighted why Antipodes believes Merck & Co is entering 2026 at an ...

The U.S. Food and Drug Administration is moving to fast-track reviews of two experimental Merck drugs with ...

Merck says Keytruda plus Padcev improved survival and response rates versus chemotherapy in a Phase 3 muscle-invasive bladder ...

Explore Pfizer Inc.’s 2025-2026 outlook: challenges, flat revenues, patent risks, and potential from the Metsera deal. Click ...

Researchers have developed a new antimalarial drug candidate designed to address the growing challenge of drug resistance and ...

It doesn't have the highest yield, but it has enviable dividend coverage and a long history of surviving in a competitive ...

Armed with new three-year data demonstrating the benefits of Anktiva in a specific patient subset, ImmunityBio is proving its bladder cancer med is still one to watch as it competes with heavy hitt | ...

Merck, Pfizer and Astellas, which in August reported similar results from a Phase 3 study of the combination in patients with muscle-invasive bladder cancer who are ineligible for cisplatin-based ...

On December 12, Morgan Stanley lifted its price target on Merck & Co., Inc. (NYSE:MRK) to $102 from $100. The firm kept an ...

Verizon's payout is higher than you'd receive from a high-yield savings account or government bonds, so it's a smart place to ...

LONDON & SAN FRANCISCO-- (BUSINESS WIRE)--December 16, 2025-- ...

“FDA is doing a thorough investigation, across multiple age groups, of deaths potentially related to coronavirus vaccines,” said Andrew Nixon, spokesperson for the U.S. Department of Health and Human ...